JUNE Medical Launches Semi-Blunt Hooks for the Galaxy II® Retractor

JUNE Medical, an international surgical device company with a reputation for innovation, has just launched 5 mm Semi-Blunt hooks for its award-winning Galaxy II® range of surgical retractors. Offering the perfect balance between the existing razor-sharp and precise Sharp hook and the more forgiving Blunt hook, the new atraumatic Semi-Blunt combines a reliable hold with less sharp penetration, staying where it is placed and allowing higher loads under more tension.

The 5 mm Semi-Blunt hooks minimize tissue trauma while maintaining a strong grip, making them ideal for challenging procedures like fistulae repair, excision of urethral diverticulum, and mesh removal surgery, where a good exposure is difficult to attain without interruption. These new hooks are both convenient and time-efficient for surgeons, as well as offering trainees improved visibility to learn surgical steps – a win-win!

Prof. Hashim Hashim, Director of the Urodynamics Unit at the Bristol Urological Institute at Southmead Hospital, commented: “For many procedures, the Blunt hooks simply can’t adequately hold onto tissues, while the Sharp ones can cause damage, as well as risking injury to the surgeon. We, therefore, needed an option that can grip tissue better without traumatizing it and, equally importantly, not cause a sharp injury to the surgeon. JUNE has listened to the surgeons and catered for that.”

Angela Spang, CEO of JUNE Medical, added: “The new Semi-Blunt hook brings together the best of both worlds – a strong, elastic hold and reduced tissue trauma. We are introducing this new hook based on feedback from the esteemed surgeons who routinely use our Galaxy II® retractors with Sharp and Blunt hooks. In a discipline like surgery, there is no room for compromise, and we aim to deliver the best tools for the surgeons and the patients.”

Find out more about the SEMI BLUNT Galaxy II® hooks visit here.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”